The CE Mark approval for Accuray's Helix system is a significant regulatory milestone, allowing the company to market this product in Europe and other regions recognizing the CE Mark. This could lead to increased sales and market expansion, particularly in emerging markets with limited access to advanced cancer care. The news is likely to positively impact Accuray's stock price in the short term as it opens new revenue opportunities.